Daniel Valenzuela M

Nuclear Medicine Physician

[Shankar Siva @_ShankarSiva]

Emerging PET tracers in RCC -—CA-IX, PSMA & sestamibi — high sensitivity/specificity for renal mass characterization & staging. Is this what the future holds in #kidneycancer ? Out now Weindler at al. @BMJ_Open https://t.co/FShjYgG2se #kcsm

[Daniel Valenzuela M @Danield_VM]

#PRIMARY2 recruitment is finished! Now it’s time to wait for the results!

[Michael Hofman @DrMHofman]

#PRIMARY2 was a rather crazy (ambitious) idea a few years ago: run of randomised trial of 660 patients to determine if PSMA PET can improve DIAGNOSIS of prostate cancer in selected men with uncertain findings on MRI, potentially reducing the need for painful biopsies.

Recruitment has completed thanks to the enthusiasm and dedication from @drlouiseemmett @DrDanielMoon @ButeauJames and the many many urologists & nuclear medicine specialists around Australia who make this happen. Thanks to all the participants and our funders @PCF_Science @pros_tic @StVincentClinic @ANZUPtrials

Clinical trial protocol here:
https://t.co/IXiKipJljF

First results 2026...

[Daniel Valenzuela M @Danield_VM]

@DrMHofman Congrats @DrMHofman @drlouiseemmett @ButeauJames @DrDanielMoon ! 👏🏻👏🏻👏🏻 Looking forward to the final results.

[Michael Hofman @DrMHofman]

#VIOLET Study of Terbium-161 (161Tb) - first trial of Beta/Auger therapy. Recently presented #ASCO25. Now out in @TheLancetOncol :
https://t.co/ulOgK3K2PA

🟣 30 patient trial in prostate cancer. No dose limiting toxicities at highest level of radioactivity (7.4 GBq)
🟣Very few side effects: 1 grade 3 lymphopenia, 1 grade 3 pain exacerbation. No grade 4. No dose delays. 🟣 Completed >6 months ahead of schedule. Thanks @Isotopia_Global for just-in-time delivery of Tb-161

Huge team involved: @ButeauJames PhD, @AzadOncology medical oncology lead, @pj_physics physics lead, @LouiseKostos PhD, @MHaskali radiochemistry, many others
🟣Funding from @PCF_Science @pros_tic @PeterMacCC @Isotopia_Global
🟣🙏patients who participated, clinical trials team, nuclear medicine team

[Daniel Valenzuela M @Danield_VM]

Webinar muy interesante y de primer nivel!!!

[ProsTIC @pros_tic]

Our webinars are back! Join us in Unravelling PSMA Biology on April 23/24 with @DrMHofman, @PCF_Science, @gu_onc and our special guest speakers: @mishabeltran, @drlouiseemmett, @EdmondMKwan & @radnucmp 🔬
Live, interactive and FREE‼️
Register now: https://t.co/NFSQHxmRaz

[Daniel Valenzuela M @Danield_VM]

@raghava_kashyap @PeterMacCC 👏🏻👏🏻👏🏻

[Daniel Valenzuela M @Danield_VM]

Outstanding work! 👏🏻👏🏻👏🏻@ButeauJames @LouiseKostos @DrMHofman The VIOLET trial is remarkable!

[Michael Hofman @DrMHofman]

We're thrilled to announce a major milestone in our first-in-human "VIOLET" study of ☢TERBIUM-161 PSMA for prostate cancer!

Not only have we seen no dose-limiting toxicities across 6 cycles up to 7.4 GBq in 30 patients treated to date, but we also wrapped up recruitment more than six months ahead of schedule. Building on this success, in a world-first, we’ve opened a new cohort at 9.5 GBq, and the first patient has just begun treatment.

Why Terbium-161?
❖ It emits additional Auger and conversion electrons beyond what Lutetium-177 offers, potentially enhancing the precision and power of treatment,
❖ Pre-clinical data demonstrates that Terbium-161 better targets small tumour clusters ("micrometastases") delivering deeper, more durable responses.

A huge thank-you to our partners who make this cutting-edge research possible:
❖ @Isotopia_Global for Terbium-161 supply and support
❖ @PCF_Science for backing this @pros_tic investigator-initiated study
❖ @PeterMacCC Foundation for providing additional funding.

Special shout out to the hard working team at Peter Mac across nuclear medicine and medical oncology that make this possible. Our star PhD candidates @ButeauJames and @LouiseKostos, lead oncologist @AzadOncology , radiopharmaceutical sciences team led by @MHaskali, medical physics @pj_physics, GU Oncology led by @declangmurphy, and many others.

Our goal? To present results of this Phase 1/2 trial later this year — a big moment in our journey to advance prostate cancer care and a "second-generation" radioligand therapy for prostate cancer.

https://t.co/vtX7EmgbjW

[Fundación Foro Nacional de Cáncer @FNCChile]

📢 Hoy, 4 de febrero, es el Día Mundial del Cáncer.

💜 Porque #PodemosHacerMás, sigamos visibilizando, apoyando y creando conciencia.

Comparte nuestro hashtag en tus redes sociales. 🎗️

@OncoMamas
#cancer #diamundialdelcancer #diamundialcontraelcancer #díamundialcontraelcáncer

[Michael Hofman @DrMHofman]

Impact of intraprostatic PSMA SUVmax following prostatectomy: a systematic review and meta-analysis

First publication of 2025 - congrats @davcmed @drMPerera

@BJUIjournal
https://t.co/jqExEUKIva

"Preoperative intraprostatic PSMA SUVmax increases monotonically with higher ISUP Grade Group and pathological tumour stage. Higher SUVmax is associated with reduced BCR-free survival. However, the use of single SUVmax thresholds for clinical decision making is not recommended as variability between studies is high."

[Michael Hofman @DrMHofman]

Very hard to pick but here are my top 10 publications from 2024 which team @pros_tic contributed to:

① (Jan’24, Lancet Oncol) TheraP follow-up: Lu-177 PSMA-617 vs cabazitaxel in mCRPC ⇒ OS ~similar, better QoL. @Prof_IanD @ANZUPtrials
https://t.co/IuKGGJXpb4

② (Feb’24, J Nucl Med) CAIX-peptide first-in-human study ⇒ High tumor uptake & new theranostics potential. @DrBenTran
https://t.co/MGMlNNIq51

③ (Mar’24, Eur Urol) LuTectomy ⇒ Lu-177 PSMA-617 pre-RP in high-risk PCa ⇒ Safe, high radiation doses achieved. @RenuEapen @ButeauJames
https://t.co/yWkpJTyz86

④ (Apr’24, Lancet) Commission ⇒ Surging PCa burden; calls for global strategies & research. @Prof_Nick_James
https://t.co/NBXcrAuPBX

⑤ (May’24, Lancet Oncol) ENZA-p ⇒ Lu-177 PSMA-617 + enzalutamide ⇒ improved PFS in mCRPC. @drlouiseemmett
https://t.co/1F3gI9sHLr

⑥ (Jun’24, Eur Urol) PSMA-PET in “nmCRPC” ⇒ Polymet disease ⇒ Worse survival vs conventional imaging. @ProfHadaschik
https://t.co/fs4nayR7aD

⑦ (Oct’24, Lancet Oncol) UpFrontPSMA ⇒ Lu-177 PSMA-617→docetaxel in high-vol mHSPC ⇒ Superior antitumor activity. @AzadOncology
https://t.co/gnbKdnJ406

⑧ (Oct'24, Eur Urol) APCCC ⇒ Expert consensus on advanced PCa imaging, therapy; highlights knowledge gaps. @Silke_Gillessen @AOmlin
https://t.co/cFCdkLKtGC

⑨ (Nov’24, Lancet Oncol) Radiotherapy & Theranostics ⇒ Global disparities, need workforce expansion. @IAEANA
https://t.co/krNautGssq

⑩ (Nov 28’24, Eur Urol Oncol) proPSMA outcomes follow-up ⇒ Baseline PSMA-PET nodal status predicts failure in high-risk PCa. @declangmurphy @veerukasi
https://t.co/RESW56MDhH

What a year in prostate theranostics !! @PCF_Science

[Thomas Hope @thomashopemd]

We are excited to host the second PSMA PET conference with @UCLATheranostic and the @PCF_Science in March. The abstract deadline is January 10th (https://t.co/AO9Nkp4Mhx). We have an incredible line up of speakers from across the globe (https://t.co/qP1QCpsODS). Please join us!

[Michael Hofman @DrMHofman]

What is my 2025 prediction for Lu-PSMA? ... Pre-chemotherapy approval

[Daniel Valenzuela M @Danield_VM]

@DrMHofman Amazing! 👏🏻

[Daniel Valenzuela M @Danield_VM]

@CancerVida @Chilesincancer @ministeriosalud

[Daniel Valenzuela M @Danield_VM]

@miprostata_cl este congreso está pasando en Melbourne, Australia en estos momento @pros_tic. Últimos tratamientos para el CaProstata. Ojalá podamos difundir en Chile

[ProsTIC @pros_tic]

3️⃣5️⃣0️⃣+ attendees 😎
2️⃣6️⃣+ countries 🌏
3️⃣8️⃣+ speakers 🗣️
3️⃣ amazing days 🤩

This is #PSMA #theranostics 🚀

This is next-gen #PrecisionOncology in Practice 🎯

This is #ProsTIC24 💪

@PeterMacCC @DrMHofman

[Daniel Valenzuela M @Danield_VM]

@AliAbdaal 20-30 min yoga nidra

[Daniel Valenzuela M @Danield_VM]

@obsdelcancer @FNCChile @CancerVida

[Daniel Valenzuela M @Danield_VM]

@Chilesincancer @miprostata_cl

[Michael Hofman @DrMHofman]

📢@ANZUPtrials #TheraP Lu-177 PSMA-617 is an alternative to cabazitaxel for men with metastatic castration-resistant prostate cancer: less toxicity and no difference in survival.
Hot of the press: https://t.co/uexhuC3oM3
@TheLancetOncol

[ProsTIC @pros_tic]

Attention Nuc Med Techs, and Theranostic enthusiasts. Register now for a @PeterMacCC Theranostic Masterclass ☢️👩‍🏫👨‍🎓. Held at our specialist Centre we are eager to share the latest in Theranostics & upskill our valued workforce. Scan 👇

[Daniel Valenzuela M @Danield_VM]

@NuevoPudahuel @LATAMAirlines Buena noticia!!! Y cuáles serán esos días de la semana? Saludos